Abstract
Purpose To ascertain the proportion of patients with neovascular age-related macular degeneration (AMD) eligible for intravitreal treatment with monoclonal antibodies to vascular endothelial growth factor, on the basis of inclusion criteria used in pivotal clinical trials.
Original language | English |
---|---|
Pages (from-to) | 1247-1251 |
Number of pages | 5 |
Journal | Eye |
Volume | 24 |
Issue number | 7 |
DOIs | |
Publication status | Published - Jul 2010 |
ASJC Scopus subject areas
- Ophthalmology